Topical rapamycin for angiofibromas in patients with tuberous sclerosis:how does it work in clinical practice?  

作　　者：Maria Palmetun Ekbäck Desiree Wiegleb Edström 

机构地区：[1]Department of Dermatology,Örebro University Hospital,70185Örebro,Sweden [2]Department of Pharmacology and Therapeutic,RegionÖrebro County Council,70185Örebro,Sweden [3]Department of Medicin Solna,Karolinska Institute and Department of Dermatology,Karolinska University Hospital,17176 Stockholm,Sweden

出　　处：《Plastic and Aesthetic Research》2016年第1期328-334,共7页整形与美容研究（英文版）

摘　　要：Aim:Topical rapamycin for angiofibromas has been reported to be a new promising treatment.This study aims to report the outcome in clinical practice.Methods:A retrospective clinical follow-up on twenty-three patients who had been prescribed an oral solution of 0.1%rapamycin,to be applied on facial lesions once a day.Results:Seventeen of 23 patients continued the treatment.Papules and nodules were improved in 8 patients(47%)and erythema in 12(70%).Side effects,such as stinging and redness were reported in 35%of patients.Blood samples were taken from 5 patients and no rapamycin could be detected.All patients who paused the treatment relapsed.Conclusion:Topical rapamycin has a positive effect on angiofibromas with improvement in both erythema and papules even if only applied every second to third day,but continuous treatment is needed.

关 键 词：Tuberous sclerosis topical rapamycin ANGIOFIBROMA clinical practice 

分 类 号：R73[医药卫生—肿瘤]